Literature DB >> 10699880

Rapid in vivo evolution of a beta-lactamase using phagemids.

J Long-McGie1, A D Liu, V Schellenberger.   

Abstract

RNA viruses are capable of undergoing extremely rapid evolution due to their high rates of reproduction, small genome size, and a high frequency of spontaneous mutagenesis. Here we demonstrate that a virus-like, evolutionary state can be created by propagating a phagemid population in a hypermutator strain of Escherichia coli in the presence of a helper phage. This enables one to subject individual phagemid-encoded genes to rapid in vivo evolution. We applied this approach to TEM-1 beta-lactamase which confers resistance to 0.05 mg/L of the antibiotic cefotaxime. After 3 weeks of in vivo evolution we were able to isolate a double mutant, E104K/G238S, of the enzyme which confers a 500-fold increased level of resistance to cefotaxime compared to the starting enzyme. In two independent experiments we obtained a triple mutant, E104K/G238S/T263M, which confers a 1000-fold increase in resistance compared to the wild type enzyme. The same three mutations have been previously observed in TEM-4 beta-lactamase which was discovered in a highly cefotaxime-resistant clinical isolate. The probability of randomly obtaining a beta-lactamase carrying three identical point mutations is less than 10(-10). This indicates that phagemid evolution can rapidly reproduce evolution occurring in nature. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699880     DOI: 10.1002/(sici)1097-0290(20000405)68:1<121::aid-bit15>3.0.co;2-x

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  9 in total

1.  Rapid evolution of novel traits in microorganisms.

Authors:  O Selifonova; F Valle; V Schellenberger
Journal:  Appl Environ Microbiol       Date:  2001-08       Impact factor: 4.792

2.  Predicting evolutionary potential: in vitro evolution accurately reproduces natural evolution of the tem beta-lactamase.

Authors:  Miriam Barlow; Barry G Hall
Journal:  Genetics       Date:  2002-03       Impact factor: 4.562

3.  Evolutionary potential of an RNA virus.

Authors:  Eugene V Makeyev; Dennis H Bamford
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

4.  Experimental evolution of gene duplicates in a bacterial plasmid model.

Authors:  Alisha K Holloway; Timothy Palzkill; James J Bull
Journal:  J Mol Evol       Date:  2007-01-08       Impact factor: 2.395

5.  Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM β-lactamases.

Authors:  Nicholas G Brown; Jeanine M Pennington; Wanzhi Huang; Tulin Ayvaz; Timothy Palzkill
Journal:  J Mol Biol       Date:  2010-10-16       Impact factor: 5.469

6.  Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic deltaampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor.

Authors:  Juan-Carlos Galán; María-Isabel Morosini; María-Rosario Baquero; Milagro Reig; Fernando Baquero
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

7.  Prolonged maltose-limited cultivation of Saccharomyces cerevisiae selects for cells with improved maltose affinity and hypersensitivity.

Authors:  Mickel L A Jansen; Pascale Daran-Lapujade; Johannes H de Winde; Matthew D W Piper; Jack T Pronk
Journal:  Appl Environ Microbiol       Date:  2004-04       Impact factor: 4.792

8.  Targeted gene evolution in Escherichia coli using a highly error-prone DNA polymerase I.

Authors:  Manel Camps; Jussi Naukkarinen; Ben P Johnson; Lawrence A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

9.  Network models of TEM β-lactamase mutations coevolving under antibiotic selection show modular structure and anticipate evolutionary trajectories.

Authors:  Violeta Beleva Guthrie; Jennifer Allen; Manel Camps; Rachel Karchin
Journal:  PLoS Comput Biol       Date:  2011-09-22       Impact factor: 4.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.